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Background: Inhaled corticosteroids (ICS) represent ﬁrst-line treatment in persistent
asthma with clinical studies showing beneﬁts of initiating therapy early. Whether
treatment should be started with a high or low dose remains controversial. We investigated
the importance of disease duration on the response to the starting dose of the ICS,
budesonide, in asthma patients not previously treated with ICS.
Methods: Forty patients with newly detected asthma (symptoms for o12 months) and 41
patients with established asthma (mean duration 5.2 years, range 2–11) were randomized
(double-blind, parallel-group) to treatment with budesonide Turbuhalers 100 or 400 mg
twice daily or placebo for 12 weeks.
Results: For morning peak expiratory ﬂow (mPEF), all four budesonide treatments
resulted in statistically signiﬁcant improvements from baseline and, after 12 weeks, the
changes in all four groups were statistically signiﬁcantly greater than placebo. In patients
receiving early treatment, no signiﬁcant differences were seen between budesonide
doses. In patients with established symptoms, 800 mg/day improved mPEF signiﬁcantly
more than 200 mg/day. The 800 mg/day dose in the early treatment group improved mPEF
signiﬁcantly more than in the delayed treatment group. Changes in forced expiratory
volume in 1 s (FEV1), the concentration of inhaled histamine causing a 20% drop in FEV1,
and use of as-needed medication behaved in very similar ways to mPEF. Asthma symptoms
were reduced in all budesonide groups without a difference between doses.
Conclusion: In patients with newly detected asthma treated early the initial ICS dose is
not important. In contrast, in patients with symptoms for a longer duration a high starting
dose improves airway function and hyperresponsiveness signiﬁcantly better than a low
dose.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
B, Skogsva¨gen 5, SE-260 83 Vejbystrand, Sweden. Tel.: +46 431 456605.
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Asthma is a chronic inﬂammatory disease and inhaled
corticosteroids (ICS) represent ﬁrst-line treatment of pa-
tients with persistent disease, irrespective of disease
severity.1 ICS should be introduced early as a delay of 2
years before starting ICS treatment may result in poorer
asthma control, i.e. lower prebronchodilator airway func-
tion, more severe bronchial hyperresponsiveness (BHR),
greater need for reliever medication and more symptoms
over time.2–4 Early treatment may also result in lower doses
of ICS over time and reduced need for other asthma drugs,
thereby being a safer and more cost-effective therapy than
a later introduction.4,5
The 10-year (1994–2004) asthma programme in Finland
aimed to reduce the burden and costs of the disease.6
An important goal was an early diagnosis and treatment.
The programme resulted in an increase in the use of ICS
from one-third of the patients in 1987 to more than 85%
both in 2001 and 2004.7 This project with ICS as ﬁrst-
line therapy for all patients with persistent asthma resulted
in a signiﬁcantly decreased burden of asthma with
fewer hospitalizations, signiﬁcant reduction in disability
pensions due to asthma, and an overall cost saving for the
management of patients with asthma.7 In most cases, the
introduction of ICS happened within a short period of time
from the ﬁrst symptoms of asthma and as a result, the
programme also proved the importance of early intervention
with ICS.
Whether treatment with ICS should be started at a high or
low dose has been debated,8 although it from a psycholo-
gical point of view appears logical to start high in order to
achieve asthma control as soon as possible. A systematic
review of 13 trials (9 using budesonide, 3 using ﬂuticasone
propionate, and 1 using beclomethasone dipropionate
[BDP]) found moderate doses of ICS (400–800 mg of BDP or
equivalent) to signiﬁcantly improve morning peak expiratory
ﬂow (mPEF) and nocturnal symptoms more than low doses
(o400 mg of BDP or equivalent), but to have no further
efﬁcacy compared with high doses (4800 mg of BDP or
equivalent).9
The effect of ICS on BHR is dose dependent and seen more
rapidly with a high than with a low dose.10 The effect of ICS
on BHR has also been shown to be a function of the ICS dose
multiplied by the duration of treatment,11 which suggests
that the change in BHR achieved with a higher dose over a
short period of time can also be achieved with a low dose
over a long period of time. Therefore, a high initial dose,
with step-wise tapering of the dose when asthma control has
been achieved, has been recommended in order to achieve
as fast as possible asthma control.6,7 Dose–response studies
both in children12 and in adults13,14 with asthma have shown
dose–response relationships with statistically signiﬁcant
differences between quadrupling doses of ICS. A meta-
analysis of 16 studies in adolescents and adults with asthma
demonstrated dose–response relationships for budesonide,
ﬂuticasone propionate and triamcinolone acetonide, but not
for mometasone furoate.15 Nevertheless, there are exam-
ples of studies with low and high doses of ICS where no
difference in response has been found between the
doses.16–19 However, the possible importance of disease
duration on response has not been studied in detail.The aim of this study was to perform a dose–response
study in two types of asthma patients, i.e. in those with a
newly detected disease (symptoms for o12 months) and
those with asthma of a longer duration (symptoms for X24
months, Figure 1).
Material and methods
Study design
This was a placebo-controlled, double-blind, parallel-group
12-week study. Eligible patients came to the clinic for six
visits: a recruitment visit followed by a 2-week run-in
period, a baseline and randomization visit, and visits after
randomized treatment for 2, 4, 8 and 12 weeks. All visits
were performed before 12.00.
The study protocol was approved by the local Ethics
committee and performed according to Good Clinical
Practice and the Declaration of Helsinki.
Key inclusion and exclusion criteria
Patients, male and female aged 18–60 years, not previously
treated with ICS or systemic corticosteroids, with a baseline
forced expiratory volume in 1 s (FEV1) ofX60% of predicted
normal, and who gave their written informed consent, were
eligible for the study when they fulﬁlled asthma criteria as
stated by the American Thoracic Society.20 Patients entered
a 2-week run-in phase where they recorded morning and
evening PEF values, asthma symptoms on a 0–3 scale and the
use of reliever medication (terbutaline 0.5mg delivered via
Turbuhalers, Bricanyls Turbuhalers—Astra Pharmaceuti-
cals Ltd., So¨derta¨lje, Sweden). Patients were randomized to
the study when they demonstrated X15% improvement in
FEV1 at visit 1 or 2 (recruitment visit and start of run-in visit)
after inhalation of 0.4mg salbutamol via a large volume
spacer, or showed X20% variability in peak expiratory ﬂow
(PEF) rates on at least 7 of the 14 run-in days. In addition,
eligible patients should have asthma symptoms (a mean
score of at least 0.5) during the last 7 days of the run-in
period and need for reliever medication on at least 4 of the
last 7 days of the run-in period.
Key exclusion criteria were a respiratory infection within
30 days before run-in, patients using systemic corticoster-
oids for any reason, and pregnant women and women not
using a reliable contraceptive method.
Study schedule
At visit 1 a medical history was obtained, including smoking
status and concomitant diseases. Skin prick tests for
common allergens were performed also if not previously
done.
The duration of patients’ asthma symptoms was carefully
recorded. Before discussions with the study personal,
patients completed a detailed questionnaire regarding their
symptoms and duration together with previous examinations
and medications. Patients with asthma symptoms for less
than 12 months formed one study group and patients with
symptoms for more than 24 months the other group.
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<12 months group
Assessed for
eligibility (n=46)
Excluded (n=5)
Not meeting
inclusion criteria (n=5)
Randomised (n=40)
(n=16)
Analysed:
(n=0) (n=0)
(n=16) (n=16)
>24 months group
Budesonide
100 μg bid
(n=16)
(n=16)
Received treatment:
Discontinued treatment:
Budesonide
400 μg bid
(n=16)
Placebo
(n=8)
(n=8)
Worsening asthma (n=5)
Assessed for
eligibility (n=63)
Excluded (n=22)
Not meeting
inclusion criteria (n=22)
Randomised (n=41)
(n=17)
(n=0)(n=2)
(n=17)(n=17)
Budesonide
100 μg bid
(n=17)
(n=7)
Discontinued treatment:
Budesonide
400 μg bid
(n=17)
Placebo
(n=7)
(n=17)
Exacerbation (n=1)
Withdrew consent (n=1)
(n=5)
(n=15)
Received treatment:
Analysed:
Figure 1 Study patient ﬂow.
ICS dose–response vs. asthma duration 1067Patients with symptoms between 12 and 24 months were
purposely excluded in order to have two distinct groups with
symptoms of clearly different durations.
In the two patient groups with different durations of
asthma symptoms, 40% of patients were randomized to
treatment with budesonide 100 mg twice daily (bid) deliv-
ered via Turbuhalers (Pulmicorts Turbuhalers, Astra
Pharmaceuticals Ltd.), 40% to budesonide 400 mg bid and
20% to placebo. All inhalers looked identical. Treatments
were started in numbered order based on computer-
generated listings, with one list for patients with a short
duration of asthma symptoms and another for those with a
longer duration of symptoms. Patients were allowed to use
terbutaline 0.5mg per dose (Bricanyls Turbuhalers) as
needed during the study but not within 6 h of a clinic visit.
Antihistamines and/or local nasal corticosteroids were
allowed for treatment of allergic rhinitis if used by the
patients prior to the study.
During the run-in phase and the study, patients completed
diary cards where they recorded morning and evening PEF
values (best of three attempts obtained with the Vitalograph
peak ﬂow meter, Clement Clark, UK), asthma symptoms on a
0–3 scale, and use of reliever medication during day and
night. Symptoms and use of reliever medication were
recorded once every 24 h. At all clinic visits spirometry
was performed (Vitalograph) when patients had been with-
out a b2-agonist for at least 6 h. At visits 2 and 6 (baseline
and end of treatment), the dose of histamine causing a 20%
fall in FEV1 (PD20 histamine) was recorded. The individualPD20 value at visit 2 did not form an exclusion or
randomization criterion. Measurements were done accord-
ing to Sovija¨rvi et al.21 with normal values being greater
than 1.6mg.
Efﬁcacy and tolerability variables
The primary efﬁcacy variable was the change in mPEF from
baseline (mean of last 7 days of the run-in period) to the end
of treatment (mean of last 7 days in the study). Other
efﬁcacy variables were evening PEF, FEV1 measured at clinic
visits, asthma symptom scores and daily use of reliever
medication (day plus night).
Safety was monitored by all patients by recording adverse
events and their severity in the diary cards. Serious adverse
events had to be immediately reported to the investigator.
Statistical analysis
No formal power calculation was performed. Based on the
results of a previous early intervention study,2 we antici-
pated that approximately 40 patients per group would be
sufﬁcient to detect a difference between the low and high
doses of budesonide. Within-group comparisons were per-
formed using t-tests. Comparisons between groups were
performed using an analysis of variance (ANOVA) with ﬁxed
factor treatment and baseline values as covariates. For
patients discontinuing the study the last values were carried
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the ANOVA analysis, all placebo-treated patients, irrespec-
tive of their duration of asthma symptoms, formed one
group. p-Values less than 0.05 were considered statistically
signiﬁcant.Results
Patient demographics
A total of 46 patients with symptoms for less than 12 months
and 63 with symptoms for more than 24 months were
screened for the study. Forty and 41 patients, respectively,
who fulﬁlled all inclusion criteria and none of the exclusion
criteria were randomized in the study. Demographic base-
line data are shown in Table 1. None of the patients had
been treated with ICS prior randomization into the study,
and all but three patients with a short duration of symptoms
had previously received bronchodilators. Patients with a
longer duration of asthma symptoms had signiﬁcantly lower
mPEF values (po0.01) and lower FEV1 values at the clinic
visit (po0.05) than patients with a short duration of
symptoms (Table 1). Patients with a longer duration of
symptoms also had signiﬁcantly more asthma symptoms at
baseline (po0.001) and used more reliever medication as
needed (po0.001). No difference in reversibility or in PD20
histamine values were seen at baseline.
Of the 40 patients with a short duration of asthma
symptoms, 32 were randomized to treatment with budeso-
nide and 8 to placebo. The corresponding ﬁgures in the
delayed therapy group were 34 and 7, respectively. Thus, a
total of 15 patients were randomized to treatment withTable 1 Patient baseline characteristics.
Characteristic Duration of asthma
symptoms o12 months
No. of patients 40
Female, n (%) 23 (72)
Mean age (7S.D.), years 37 (12)
No. of smokers 2
No of patients with positive skin
prick tests
25
No. of patients with allergic rhinitis 12
Median duration of asthma
symptoms (range)
7.5 months (2–10)
Mean (7S.D.) FEV1, L 3.21 (0.80)
Range 1.74–5.22
Mean (7S.D.) FEV1% predicted 86.5 (5.3)
Range 72.1–122.4
Mean (7S.D.) reversibility, % 23.6 (2.5)
Range 16.2–28.6
Mean (7S.D.) morning PEF, L/min 452 (32)
Range 282–520
Mean (7S.D.) morning PEF, %
predicted
84.9 (8.7)
PD20 histamine, mg 0.22 (0.36)
Asthma symptom score 1.3 (0.7)
Puffs of b2-agonists per day 2.0 (0.5)placebo. Within the respective groups there were no
important differences between patients randomized to low
or high dose of budesonide or placebo.
All randomized patients except seven completed the
study. Five patients randomized to placebo wanted to
discontinue because of worsening asthma after being in
the study for 14, 17, 21, 25 and 54 days. One patient in the
low-dose delayed therapy group developed an exacerbation
after being in the study for 48 days and another patient in
the same group withdrew consent after 1 week in the study.Peak expiratory ﬂow
In both early and delayed treatment groups and with both
budesonide doses, mPEF improved from baseline and from
visit to visit in patients treated with budesonide compared
with placebo (Figure 2, Table 2). For both doses in the early
treatment group and for the high dose in the delayed
treatment group the difference compared with placebo
became statistically signiﬁcant already after treatment for 2
weeks (Figure 2, Table 2). In the early treatment group no
statistically signiﬁcant difference in improvement in mPEF
was found between the low and the four times higher dose
of budesonide (p ¼ 0.266) (Table 2). However, in the
delayed treatment group, 400 mg bid of budesonide im-
proved mPEF signiﬁcantly more than the low dose of
budesonide, 100 mg bid (p ¼ 0.031) (Table 2).
The low dose of budesonide resulted in a signiﬁcantly
greater improvement in mPEF in the early treatment
group compared with the same dose in the delayed
treatment group (p ¼ 0.021). No statistically signiﬁcant
difference was seen between the high dose treatments inDuration of asthma
symptomsX24 months
p-Value
41
20 (59) NS
42 (14) NS
3 NS
28 NS
10 NS
5.2 years (2–11)
2.85 (0.78) o0.05
1.58–4.96
78.8 (8.1) o0.05
65.8–110.2
24.2 (1.9) NS
15.6–35.0
416 (67) o0.01
216–478
77.5 (10.6) o0.01
0.17 (0.62) NS
2.0 (0.8) o0.001
3.6 (1.3) o0.001
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(p ¼ 0.560) (Table 2).
The changes in evening PEF from baseline to the end of
the study mirrored the changes in mPEF and are shown in
Table 2. Values for the different visits are not presented.Forced expiratory volume in 1 s (FEV1)
In both early and delayed treatment groups, FEV1 improved
gradually in patients treated with budesonide compared
with placebo (Figure 3, Table 2). In the early treatment
group no statistically signiﬁcant difference was found
between the low and the four times higher dose of
budesonide (p ¼ 0.127) (Table 2). However, in the delayed
treatment group budesonide 400 mg bid improved FEV1
signiﬁcantly more than the 100 mg bid dose of budesonide
(p ¼ 0.018) (Table 2).PD20 histamine
In both the early and delayed budesonide groups, PD20
increased signiﬁcantly compared with placebo (Table 2). In
the early treatment group, the difference in change in
PD20 between the doses of budesonide was not signiﬁcant
(p ¼ 0.46) but in the delayed treatment group the
higher dose improved PD20 signiﬁcantly better (p ¼ 0.009)
(Table 2).Asthma symptoms
Asthma symptom scores at baseline and at the end of the
study are shown in Table 2. A signiﬁcant reduction in
symptoms was noticed in all budesonide groups compared
with placebo. There were no statistically signiﬁcant differ-
ences in change of symptoms between the low and the
higher dose groups, neither in patients with a short, nor in
those with a longer duration of symptoms (Table 2).M
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Figure 2 Percent predicted of mPEF in patients receiving early tre
treatment (asthma symptoms for more than 24 months) with 100
Statistically signiﬁcant differences between the two budesonide doUse of reliever medication
A signiﬁcant reduction in b2-agonist use was seen in all
budesonide groups compared with placebo except for the
low budesonide dose in the delayed therapy group (Table 2).
There were no statistically signiﬁcant differences in change
of reliever medication use between the low and the higher
dose groups in patients with a short duration of symptoms
(p ¼ 0.174), but a signiﬁcant difference between the doses
in patients with a longer duration of symptoms (p ¼ 0.047)
(Table 2).Tolerability
No serious adverse events were reported. A total of 24
adverse events in 17 patients were recorded: 9 in the
placebo group (upper respiratory tract infection 3, sore
throat 2, headache 1, vomiting 1, back pain 1, bicycle
accident 1), 3 in the early low group (upper respiratory tract
infection 1, epigastric pain 1, restless legs 1), 3 in the early
higher dose budesonide group (sore throat 1, itching 1,
headache 1), 7 in the delayed low group (upper respiratory
tract infection 2, headache 2, coughing 1, tremor 1,
diarrhea 1) and 2 in the delayed high budesonide group
(shoulder pain 1, ear ache 1). All adverse events were
classiﬁed as mild except one case of moderate–severe
headache. All adverse events were transient.Discussion
For many years now, it has been debated whether treatment
with ICS in asthma should be initiated with a high or a low
dose.7,17 The GINA guidelines give no advice but state that
patients should have the lowest possible dose of ICS that
gives an adequate asthma control.1 A systematic review
found moderate doses of ICS as a starting dose to improve
mPEF signiﬁcantly better than a low dose.8
In the study by Haahtela et al.2 demonstrating the
advantage of early intervention with ICS in newly detected∗∗
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Table 2 Efﬁcacy results (mean7S.D.) in patients with asthma symptoms foro12 months orX24 months at baseline and after treatment for 12 weeks with a low or high dose
of budesonide.
Variable Early treatment Delayed treatment Placebo (n ¼ 15) (8 early+
7 delayed)
Budesonide 100mg bid
(n ¼ 16)
Budesonide 400 mg bid
(n ¼ 16)
Budesonide 100mg bid
(n ¼ 17)
Budesonide 400mg bid
(n ¼ 17)
Baseline 12 weeks
Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks Baseline 12 weeks
Morning PEF, L/min 408 (36) 451 (27),y 426 (29) 479 (38),y 376 (46) 405 (33)z 389 (54) 446 (56)y,y 402 (60) 418 (56)
Evening PEF, L/min 427 (49) 472 (37)y,y 430 (40) 493 (56),y 392 (48) 428 (52)z,y 410 (65) 459 (67)z,y 428 (76) 426 (67)
FEV1, L 3.24 (0.61) 3.80 (0.42)
y,y 3.19 (0.68) 3.83 (0.43)y,y 2.88 (0.72) 3.11 (0.75) 2.81 (0.58) 3.23 (0.61)z,z 3.02 (0.66) 3.10 (0.67)
PD20 histamine, mg/mL 0.32 (0.48) 0.94 (0.41)
,y 0.18 (0.42) 1.10 (0.37),y 0.24 (0.34) 0.47 (0.50)J 0.16 (0.52) 0.98 (0.32),y 0.56 (0.32) 0.49 (0.38)
Asthma symptoms, scale 0–3 1.5 (0.8) 0.5 (0.6),y 1.2 (0.6) 0.2 (0.7),y 2.2 (0.6) 0.9 (0.8),J 1.8 (0.8) 0.3 (0.9),y 2.0 (0.9) 1.8 (0.8)
b2 use/day, no. of puffs 2.0 (0.6) 0.6 (0.2)
,y 1.9 (0.7) 0.2 (0.2),y 3.5 (0.6) 3.0 (0.8)z 4.0 (0.7) 1.5 (0.5),y 3.0 (0.9) 3.1 (1.2)
Baseline values for PEF, asthma symptoms and b2-agonist use are mean values of the last 7 days of the run-in period.
po0.001.
ypo0.01.
zpo0.05 vs. baseline.
ypo0.001.
zpo0.01.
Jpo0.05 vs. placebo.
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Figure 3 Percent increase in FEV1 from baseline to end of the study in patients receiving early treatment (asthma symptoms for less
than 12 months) and delayed treatment (asthma symptoms for more than 24 months) with 100 or 400 mg bid of budesonide. Mean
values7S.D. are shown. Statistically signiﬁcant differences between the two budesonide doses are shown; *po0.05, **po0.01.
ICS dose–response vs. asthma duration 1071asthma, initial treatment was given with a high-dose
budesonide, 1200 mg daily via a pMDI plus spacer and
followed after 2 years with 400 mg daily via Turbuhalers
for a third study year. Starting high has, thereafter, been the
recommendation in the Finnish asthma guidelines,6,22 and
this recommendation was reinforced with the results of the
Finnish 10-year asthma programme.7 Maintenance treat-
ment can mostly be given with a much lower dose,2,5,23
which should be the lowest possible dose that maintains
good asthma control.1
Patients and physicians who are concerned about potential
ICS-induced side-effects prefer to start treatment with a low-
dose ICS or with alternative medications. There are, however,
reasons why starting high may be a better option. First, as BHR
improves more rapidly with a higher dose10,11 and symptom
control is equally achieved more rapidly with a higher dose of
ICS,13,14 such a dosing schedule will increase patients’
conﬁdence in the treatment. A patient fearing side-effects
is not happy when the treating physician has to recommend an
increase in dose from visit to visit in order to obtain
satisfactory asthma control. Second, follow-up studies have
shown that the cumulative dose of ICS will be lower if
treatment is started with a high dose compared with a low
dose4,5 and thereby the long-term safety proﬁle will improve.
It has also been found that the actual maintenance doses of
ICS are lower in patients who have been treated early with ICS
compared with patients receiving delayed treatment.4,5,24
In children with asthma, treatment with ICS improves
asthma control compared with alternative treatment regi-
mens.24,25 It appears, however, that ICS may not inﬂuence
the long-term decline26 in FEV1 and therefore alternative
treatments25,27 and a delay with starting ICS treatment in
children has been proposed as an equally good asthma
management plan.28 The reason for this may be that it takes
time before a more ﬁxed airway obstruction develops in
children compared with adults with asthma.
As early intervention with ICS in adult patients with
persistent asthma has been found to result in better asthma
control in terms of prebronchodilator FEV1, mPEF values,
asthma symptoms and use of reliever medication,2–4 thisstudy was initiated to evaluate whether the starting dose of
ICS is important. We also wanted to study whether the initial
response to ICS is different in patients with newly detected
asthma (symptoms foro12 months) compared with patients
with a longer duration of asthma symptoms. In order to
obtain distinct groups, patients with a symptom duration
between 12 and 24 months were excluded.
In patients with a short duration of asthma symptoms
(early treatment group) no statistically signiﬁcant differ-
ences between the low and the high doses of budesonide
were found. Both doses improved airway function, reduced
asthma symptoms and reduced the need for reliever
medication compared with placebo. Also, no important
difference in change in PD20 histamine was found, although
the higher dose improved BHR somewhat faster.
Estimation of symptom duration is of course far from an
exact science. It is obvious that some patients may have
suffered from lower airway symptoms or even diagnosed
asthma during childhood but they may have totally forgotten
this. Even if asthma is said to begin in childhood it may be
that the differences in long-term outcomes are not
determined until later in life when symptoms reappear.
Therefore, it is not without interest to compare the
response to ICS in patient groups with different duration
of asthma symptoms during adulthood when starting
therapy. This study demonstrated the importance of dose
selection in patients who had had asthma symptoms for a
mean of more than 5 years.
In patients with delayed introduction of ICS, both doses of
budesonide improved all variables studied compared with
placebo but the higher dose of budesonide was signiﬁcantly
better than the low dose with regards to airway function and
PD20 histamine.
There were differences between the groups at baseline in
terms of airway function, asthma symptoms and use of
reliever medication as needed. This is a weakness of the
study. The ideal would of course have been to select
patients for both groups matched for these variables.
Unfortunately this was not possible with the series of
patients available at the time of the study. Patients with
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ICS, almost always had a more severe asthma than patients
with a newly detected disease. Another weakness of the
study is that the vast majority of the patients were known to
the investigator. Therefore, the study group of a patient
may have been known although the randomization to low or
higher dose of budesonide or placebo remained blinded.
Despite these shortcomings, it appears possible to
conclude based on these study results that starting with a
higher dose of budesonide may be clinically important in
adult patients with a longer duration of asthma. In patients
with a duration of asthma symptomso12 months the choice
of starting dose does not seem to matter.
Conﬂict of interest statement
The author was a full-time employee of AstraZeneca until
2001. Thereafter, he has performed consultancy work for
several different companies, including AstraZeneca R&D,
Lund.
Acknowledgments
The principal investigator of this study was Dr. Markus Niemisto¨,
MD, who died before compiling and publishing these data. A
part of the study was reported at the American Thoracic
Society meeting in 1999. The study was supported by a research
grant from the Mjo¨lbolsta hospital foundation for clinical
research. The author, who was the supervisor of the study has
presented the results in honor of his colleague whose work was
greatly appreciated. He also would like to thank O¨ Widjeskog,
Ph.D., Turku, Finland, for statistical analysis of these data and A
Lindholm, RN, for internal monitoring of the study.
References
1. Global Initiative for Asthma (GINA). Global strategy for asthma
management and prevention. Available from: /http://www.gi-
nasthma.orgS; 2006.
2. Haahtela T, Ja¨rvinen M, Kava T, et al. Effects of reducing or
discontinuing inhaled budesonide in patients with mild asthma.
N Engl J Med 1994;331:700–5.
3. Selroos O, Pietinalho A, Lo¨froos A-B, et al. Effect of early vs late
intervention with inhaled corticosteroids in asthma. Chest
1995;108:1228–34.
4. Selroos O, Lo¨froos A-B, Pietinalho A, et al. Asthma control and
steroid doses 5 years after early or delayed introduction of
inhaled corticosteroids in asthma: a real-life study. Respir Med
2004;98:254–62.
5. Haahtela T, Tamminen K, Malmberg LP, et al. Follow-up results 10
years after early intervention with budesonide or terbutaline in
mild persistent asthma. Eur Respir J 2006;28(Suppl. 50):667s.
6. Asthma programme in Finland 1994–2004, with introduction
Haahtela T, Laitinen LA. Clin Exp Allergy 1996;26:1–24.
7. Haahtela T, Tuomisto LE, Pietinalho A, et al. A 10 year asthma
programme in Finland: major change for the better. Thorax
2006;61:663–70.
8. van der Molen T, Kerstjens HAM. Starting inhaled corticosteroids
in asthma: when, how high, and how long. Eur Respir J 2000;
15:3–4.9. Powell H, Gibson PG. Initial starting dose of inhaled corticos-
teroids in adults with asthma: a systematic review. Thorax
2004;59:1041–5.
10. Kraan J, Koeter GH, van der Mark TW, et al. Dosage and time
effects of inhaled budesonide on bronchial hyperreactivity. Am
Rev Respir Dis 1988;137:44–8.
11. Postma DS, Kerstjens HA, Koeter GH. In: Postma DS, Gerritsen
JN, editors. Long-term intervention in disease outcome. Assen:
Bronchitis V. van Gorcum; 1994. p. 253–66.
12. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efﬁcacy
of budesonide administered via a dry powder inhaler in the
treatment of children with moderate to severe persistent
asthma. J Pediatr 1998;132:976–82.
13. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered
by Turbuhaler is effective in a dose-dependent fashion when
used in the treatment of adult patients with chronic asthma.
J Allergy Clin Immunol 1998;102:457–63.
14. Miyamoto T, Takahashi T, Nakajima S, et al. A double-blind,
placebo-controlled dose–response study with budesonide Tur-
buhaler in Japanese asthma patients. Respirology 2000;5:
247–56.
15. Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A
meta-analysis of the dose–response relationships of inhaled
corticosteroids in adolescents and adults with mild to moderate
persistent asthma. Clin Ther 2002;24:1–20.
16. Boe J, Rosenhall L, Alton M, et al. Comparison of dose–response
effects of inhaled beclomethasone dipropionate and budeso-
nide in the management of asthma. Allergy 1989;44:349–55.
17. van der Molen T, Meyboom-de Jong B, Muldur HH, et al. Starting
with a higher dose of inhaled corticosteroids in primary care
asthma treatment. Am J Respir Crit Care Med 1998;158:121–5.
18. Gershman NH, Wong HH, Liu JT, et al. Low- and high-dose
ﬂuticasone propionate in asthma; effects during and after
treatment. Eur Respir J 2000;15:11–8.
19. Selroos O. Some aspects on comparative efﬁcacy studies with
inhaled corticosteroids in asthma. Curr Drug Ther 2007;2:
57–74.
20. American Thoracic Society. Standards for the diagnosis and care
of patients with chronic obstructive pulmonary disease (COPD)
and asthma. Am Rev Respir Dis 1987;136:225–44.
21. Sovija¨rvi ARA, Malmberg P, Reinikainen K, et al. A rapid
dosimetric method with controlled tidal breathing for histamine
challenge. Chest 1993;104:164–70.
22. Astman diagnostiikka ja hoito, Ka¨ypa¨ hoito suositus (Diagnosis
and treatment of asthma, evidence based current care guide-
line) Duodecim 2000;116:2568–94. Updated 2006 [in Finnish].
23. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose
inhaled budesonide and formoterol in mild persistent asthma.
The OPTIMA randomized trial. Am J Respir Crit Care Med
2001;164:1392–7.
24. Agertoft L, Pedersen S. Effects of long-term treatment with an
inhaled corticosteroid on growth and pulmonary function in
asthmatic children. Respir Med 1994;88:373–81.
25. Turpeinen M, Nikander K, Pelkonen AS, et al. Daily versus as-
needed inhaled corticosteroid for mild persistent asthma. Arch
Dis Child [published online July 18, 2007].
26. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled
corticosteroids in preschool children at high risk for asthma. N
Engl J Med 2006;354:1985–97.
27. Boushey HA, Sorkness CA, King TS, et al. Daily versus as needed
corticosteroids for mild persistent asthma. N Engl J Med 2005;
352:1519–28.
28. CAMP. The Childhood Asthma Management Research Group.
Long-term effects of budesonide or nedocromil in children with
asthma. N Engl J Med 2000;343:1054–63.
